Literature DB >> 20833716

Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes.

Yukie Iwabu1, Masanobu Kinomoto, Masashi Tatsumi, Hideaki Fujita, Mari Shimura, Yoshitaka Tanaka, Yukihito Ishizaka, David Nolan, Simon Mallal, Tetsutaro Sata, Kenzo Tokunaga.   

Abstract

Antiretroviral cytidine deaminase APOBEC3G, which is abundantly expressed in peripheral blood lymphocytes and macrophages, strongly protects these cells against HIV-1 infection. The HIV-1 Vif protein overcomes this antiviral effect by enhancing proteasome-mediated APOBEC3G degradation and is key for maintaining viral infectivity. The 579-bp-long vif gene displays high genetic diversity among HIV-1 subtypes. Therefore, it is intriguing to address whether Vif proteins derived from different subtypes differ in their viral defense activity against APOBEC3G. Expression plasmids encoding Vif proteins derived from subtypes A, B, C, CRF01_AE, and CRF02_AG isolates were created, and their anti-APOBEC3G activities were compared. Viruses produced from cells expressing APOBEC3G and Vif proteins from different subtypes showed relatively different viral infectivities. Notably, subtype C-derived Vif proteins tested had the highest activity against APOBEC3G that was ascribed to its increased binding activity, for which the N-terminal domain of the Vif protein sequences was responsible. These results suggest that the biological differences of Vif proteins belonging to different subtypes might affect viral fitness and quasispecies in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20833716      PMCID: PMC2975159          DOI: 10.1074/jbc.M110.173286

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  82 in total

1.  Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.

Authors:  Craig Pace; Jean Keller; David Nolan; Ian James; Silvana Gaudieri; Corey Moore; Simon Mallal
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity.

Authors:  Ying Dang; Roderick W Davis; Ian A York; Yong-Hui Zheng
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

3.  Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation.

Authors:  Andrew Mehle; Joao Goncalves; Mariana Santa-Marta; Mark McPike; Dana Gabuzda
Journal:  Genes Dev       Date:  2004-12-01       Impact factor: 11.361

4.  The role of mononuclear phagocytes in HTLV-III/LAV infection.

Authors:  S Gartner; P Markovits; D M Markovitz; M H Kaplan; R C Gallo; M Popovic
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

5.  Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes.

Authors:  Lubbertus C F Mulder; Marcel Ooms; Susan Majdak; Jordan Smedresman; Caitlin Linscheid; Ariana Harari; Andrea Kunz; Viviana Simon
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

6.  Full-length sequence of an ethiopian human immunodeficiency virus type 1 (HIV-1) isolate of genetic subtype C.

Authors:  M O Salminen; B Johansson; A Sönnerborg; S Ayehunie; D Gotte; P Leinikki; D S Burke; F E McCutchan
Journal:  AIDS Res Hum Retroviruses       Date:  1996-09-20       Impact factor: 2.205

7.  A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G.

Authors:  Gongying Chen; Zhiwen He; Tao Wang; Rongzhen Xu; Xiao-Fang Yu
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

8.  Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates.

Authors:  Véronique Zennou; Paul D Bieniasz
Journal:  Virology       Date:  2006-02-07       Impact factor: 3.616

9.  The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.

Authors:  Tonie Cilliers; Jabulani Nhlapo; Mia Coetzer; Dragana Orlovic; Thomas Ketas; William C Olson; John P Moore; Alexandra Trkola; Lynn Morris
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

10.  APOBEC3G targets human T-cell leukemia virus type 1.

Authors:  Amane Sasada; Akifumi Takaori-Kondo; Kotaro Shirakawa; Masayuki Kobayashi; Aierkin Abudu; Masakatsu Hishizawa; Kazunori Imada; Yuetsu Tanaka; Takashi Uchiyama
Journal:  Retrovirology       Date:  2005-05-19       Impact factor: 4.602

View more
  31 in total

1.  The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.

Authors:  Mawuena Binka; Marcel Ooms; Myeika Steward; Viviana Simon
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

Review 2.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

3.  Natural Single-Nucleotide Variations in the HIV-1 Genomic SA1prox Region Can Alter Viral Replication Ability by Regulating Vif Expression Levels.

Authors:  Masako Nomaguchi; Naoya Doi; Yosuke Sakai; Hirotaka Ode; Yasumasa Iwatani; Takamasa Ueno; Yui Matsumoto; Yasuyuki Miyazaki; Takao Masuda; Akio Adachi
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

4.  Accessory genes confer a high replication rate to virulent feline immunodeficiency virus.

Authors:  Ryan M Troyer; Jesse Thompson; John H Elder; Sue VandeWoude
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

5.  Subtype-Specific Differences in Gag-Protease-Driven Replication Capacity Are Consistent with Intersubtype Differences in HIV-1 Disease Progression.

Authors:  Marion W Kiguoya; Jaclyn K Mann; Denis Chopera; Kamini Gounder; Guinevere Q Lee; Peter W Hunt; Jeffrey N Martin; T Blake Ball; Joshua Kimani; Zabrina L Brumme; Mark A Brockman; Thumbi Ndung'u
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

6.  Single-Strand Consensus Sequencing Reveals that HIV Type but not Subtype Significantly Impacts Viral Mutation Frequencies and Spectra.

Authors:  Jonathan M O Rawson; Daryl M Gohl; Sean R Landman; Megan E Roth; Morgan E Meissner; Tara S Peterson; James S Hodges; Kenneth B Beckman; Louis M Mansky
Journal:  J Mol Biol       Date:  2017-05-11       Impact factor: 5.469

7.  Determinants of efficient degradation of APOBEC3 restriction factors by HIV-1 Vif.

Authors:  Tayyba T Baig; Yuqing Feng; Linda Chelico
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

8.  Rev-RRE Functional Activity Differs Substantially Among Primary HIV-1 Isolates.

Authors:  Patrick E Jackson; Denis M Tebit; David Rekosh; Marie-Louise Hammarskjold
Journal:  AIDS Res Hum Retroviruses       Date:  2016-06-03       Impact factor: 2.205

9.  A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2/Tetherin and enhance viral egress.

Authors:  Janet L Douglas; Ying Bai; Jean K Gustin; Ashlee V Moses
Journal:  Virology       Date:  2013-04-10       Impact factor: 3.616

10.  Functional characterization of Vif proteins from HIV-1 infected patients with different APOBEC3G haplotypes.

Authors:  Kavidha Reddy; Marcel Ooms; Michael Letko; Nigel Garrett; Viviana Simon; Thumbi Ndung'u
Journal:  AIDS       Date:  2016-07-17       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.